共 220 条
[1]
Hauser SL(2008)B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med 358 676-688
[2]
Waubant E(2010)Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial Neurology. 74 1860-1867
[3]
Arnold DL(2008)Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial Ann Neurol 63 395-400
[4]
Vollmer T(2018)Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study J Neurol 265 1690-1697
[5]
Antel J(2016)Rituximab in multiple sclerosis Neurology. 87 2074-2081
[6]
Fox RJ(2019)Effectiveness and safety of rituximab in demyelinating diseases spectrum: an Italian experience Mult Scler Relat Disord 27 324-326
[7]
Bar-Or A(2018)Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry Mult Scler J 24 1087-1095
[8]
Panzara M(2018)Effectiveness and safety of rituximab in multiple sclerosis: an observational study from southern Switzerland PLoS One 13 e0197415-152
[9]
Sarkar N(2019)Rituximab treatment for multiple sclerosis Mult Scler J 135245851985860 137-302
[10]
Agarwal S(2011)Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria Ann Neurol 69 292-120